^
    Back
    Association details:
    Biomarker:FLT3 F691L
    Cancer:Acute Myelogenous Leukemia
    Drug:Vanflyta (quizartinib) (FLT3 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Nature
    Title:

    Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

    Excerpt:
    ...evolution of AC220-resistant substitutions at two of these amino acid positions was observed in eight of eight FLT3-ITD-positive AML patients with acquired resistance to AC220….The activation loop mutation D835Y was detected in three cases, D835V in two, and the gatekeeper mutation F691L was identified in three....
    DOI:
    https://dx.doi.org/10.1038%2Fnature11016
    Trial ID:
    NCT00989261
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Cancer Discov
    Title:

    Characterizing and Overriding the Structural Mechanism of the Quizartinib-resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397

    Excerpt:
    We performed proliferation studies of PLX3397 and quizartinib for Ba/F3 cells expressing FLT3-ITD and FLT3-ITD/F691L and confirmed that PLX3397, in contrast to quizartinib, has the ability to inhibit the proliferation of both isoforms...
    DOI:
    https://dx.doi.org/10.1158%2F2159-8290.CD-15-0060